BioNTech Results Presentation Deck

Q2 2021 and 6M 2021 COVID-19 Vaccine Deliveries Drove Revenue Growth €5,266.0m 36 COVID-19 vaccine revenues €138.1m €14.5m €5,280.5m €4,092.3m €1,035.6m Q2 2021 €7,308.0m €5,844.2m €1,235.4m €202.0m 6M 2021 €26.4m Commercial revenues - identified revenue streams COVID-19 vaccine revenues €7,281.6m *Represents an estimated figure based on preliminary data shared between Pfizer and BioNTech. Changes in share of the collaboration partner's gross profit will be recognized prospectively. Share of gross profit from COVID-19 vaccine sales in the Pfizer and Fosun territory (net position) and sales milestones (€168.6m for Q2 2021 and €415.8m for 6M 2021, respectively)* Direct COVID-19 vaccine sales to customers in BioNTech's territory Sales to collaboration partners of products manufactured by BioN Tech Other sales (mainly JPT and IMFS business) BIONTECH

View entire presentation